Jubilant Life Sciences has reported results for the fourth quarter and year ended March 31, 2019.
The company has reported a fall of 91.39% in its net profit at Rs 7.44 crore for the quarter ended March 31, 2019 as compared to Rs 86.39 crore for the same quarter in the previous year. Total income of the company decreased by 10.53% at Rs 869.95 crore for quarter under review as compared to Rs 972.32 crore for the quarter ended March 31, 2018.
On consolidated basis, the company has reported a net loss of Rs 100.65 crore for the quarter ended March 31, 2019 against net profit of Rs 152.40 crore for the corresponding quarter in the FY18. However, total consolidated income of the company rose marginally by 4.58% at Rs 2,379.00 crore for quarter under review as compared to Rs 2,274.87 crore for the same quarter ended previous year.
For the year ended March 31, 2019, the company has posted a fall of 44.18% in its net profit at Rs 147.06 crore as compared to Rs 263.44 crore for the previous year. However, total income of company increased marginally by 3.76% at Rs 3,516.61 crore for year under review as compared to Rs 3,389.22 crore for year ended March 31, 2018.
For the year ended March 31, 2019, on the consolidated basis, the company has posted fall of 9.05% in its net profit at Rs 577.01 crore as compared to Rs 634.42 crore for the previous year. However, total income of company increased by 20.38% at Rs 9,146.56 crore for year under review as compared to Rs 7,597.84 crore for year ended March 31, 2018.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: